Literature DB >> 15780742

DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys.

Kerrie Vaughan1, Gary H Rhodes, Laurel J Gershwin.   

Abstract

A DNA vaccine was tested in infant Rhesus macaques to evaluate its safety, immunogenicity and protective efficacy. Monkeys were vaccinated and challenged with a clinical isolate of human RSV. Vaccinated animals developed humoral and cellular responses following inoculation with plasmid DNA encoding the fusion (F) and nucleoprotein (N), from closely related bovine RSV. Vaccinated monkeys had decreased RSV in their lungs post-infection, and there was a qualitative difference in histopathology observed between vaccinated and unvaccinated animals. The combined result of safety and immunogenicity in a neonatal primate model is encouraging, suggesting the feasibility of DNA vaccines against RSV in infants.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15780742     DOI： 10.1016/j.vaccine.2004.10.046

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  14 in total

1.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 2.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

Review 3.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

4.  Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection.

Authors:  Robert Jordan; Matt Shao; Richard L Mackman; Michel Perron; Tomas Cihlar; Sandy A Lewis; Eugene J Eisenberg; Anne Carey; Robert G Strickley; Jason W Chien; Mark L Anderson; Heather A McEligot; Nicole E Behrens; Laurel J Gershwin
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

5.  DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge.

Authors:  Mathieu Boxus; Marylène Tignon; Stefan Roels; Jean-François Toussaint; Karl Walravens; Marie-Ange Benoit; Philippe Coppe; Jean-Jacques Letesson; Carine Letellier; Pierre Kerkhofs
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

6.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

7.  RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.

Authors:  Hongzhuan Wu; Vida A Dennis; Shreekumar R Pillai; Shree R Singh
Journal:  Virus Res       Date:  2009-06-21       Impact factor: 3.303

8.  Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.

Authors:  Aude Remot; Xavier Roux; Catherine Dubuquoy; Jenna Fix; Stephan Bouet; Mohammed Moudjou; Jean-François Eléouët; Sabine Riffault; Agnès Petit-Camurdan
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

9.  Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.

Authors:  Xavier Roux; Catherine Dubuquoy; Guillaume Durand; Thi-Lan Tran-Tolla; Nathalie Castagné; Julie Bernard; Agnès Petit-Camurdan; Jean-François Eléouët; Sabine Riffault
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

10.  Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes.

Authors:  Liulin Chen; Junming Zhu; Yuhong Li; Jie Lu; Li Gao; Huibi Xu; Mingwen Fan; Xiangliang Yang
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.